**Abstract**

**Objective:** Approximately 10% of pregnant women are prescribed antidepressant drugs, most commonly the selective serotonin reuptake inhibitor, Fluoxetine. Fluoxetine crosses the placenta and is excreted in breast milk raising concerns regarding the consequences of infant exposure. The aim of this study was to evaluate the effects of maternal Fluoxetine treatment on offspring behaviours of relevance to neurodevelopmental and psychiatric disorders, using a rodent model of depression.

**Methods:** Sprague-Dawley (SD; healthy model) and Wistar-Kyoto (WKY; depression model) pregnant rats were treated with Fluoxetine (10mg/kg/day) or vehicle, from gestational day 0 to postnatal day 14 (∼5 weeks in total). Once offspring reached adolescence (∼5 weeks of age), locomotor activity, anxiety-like and depressive-like behaviours were assessed using the open field test (OFT), elevated plus maze (EPM) and forced swim test (FST).

**Results:** Fluoxetine exposed offspring displayed an increase in distance travelled in the OFT, an effect that was independent of rat strain and sex. Fluoxetine exposure also caused an increase (up to 50%) in time spent in the corners of the OFT in SD male and WKY female rats compared to their respective vehicle controls. Similarly, in the EPM, maternal Fluoxetine treatment resulted in a significant increase in time spent in the closed arms in SD males and WKY males (29--52%). A similar trend was observed in females, but this did not reach significance. In the FST, maternal Fluoxetine treatment increased immobility time in exposed offspring (28%), an effect that was independent of strain or sex.

**Conclusion:** Maternal Fluoxetine treatment resulted in significant increases in anxiety-like and depressive-like behaviours in exposed offspring, largely independent of the rat model used. However, further studies in various models of maternal depression are required to confirm these preliminary findings and establish the effects of Fluoxetine exposure on the developing brain.
